In vitro studies have reported significant anti-tumour activity of dacomitinib in gefitinib-resistant lung cancer as well as breast cancer cell lines which are resistant to trastuzumab and lapatinib (a dual HER2 and EGFR inhibitor)37, 38. The gene discussed is ERBB2; the disease is breast carcinoma.